Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCLK1 | O15075 | 7/20 | 1.00 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.76 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.76 |
| ▸ | PIK3C2G | O75747 | 7/20 | 0.76 |
| ▸ | PIK3CG | P48736 | 7/20 | 0.76 |
| ▸ | AURKA | O14965 | 5/20 | 0.76 |
| ▸ | AURKB | Q96GD4 | 5/20 | 0.76 |
| ▸ | MAPK7 | Q13164 | 5/20 | 0.76 |
| ▸ | BRD4 | O60885 | 4/20 | 0.73 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.57 |
| ▸ | STK3 | Q13188 | 1/20 | 0.55 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18371573 | 0.89 | PIK3CG (0.83) | DCLK1LRRK2PIK3CDPIK3C2GPIK3CG | |
| SCHEMBL20628568 | 0.89 | DCLK1 (0.80) | DCLK1LRRK2PIK3CDPIK3C2GPIK3CG | |
| SCHEMBL20628481 | 0.89 | DCLK1 (0.80) | DCLK1LRRK2PIK3CDPIK3C2GPIK3CG | |
| SCHEMBL20094144 | 0.89 | DCLK1 (0.80) | DCLK1LRRK2PIK3CDPIK3C2GPIK3CG | |
| SCHEMBL17519893 | 0.88 | DCLK1 (0.78) | DCLK1LRRK2PIK3CDPIK3C2GPIK3CG | |
| SCHEMBL10098763 | 0.86 | PIK3CG (1.00) | DCLK1LRRK2PIK3CDPIK3C2GPIK3CG | |
| SCHEMBL22663711 | 0.85 | PIK3CG (0.80) | DCLK1LRRK2PIK3CDPIK3C2GPIK3CG | |
| SCHEMBL20094404 | 0.85 | LRRK2 (1.00) | DCLK1LRRK2PIK3CDPIK3C2GPIK3CG | |
| SCHEMBL20628558 | 0.85 | DCLK1 (0.73) | DCLK1LRRK2PIK3CDPIK3C2GPIK3CG | |
| SCHEMBL20628559 | 0.84 | DCLK1 (0.72) | DCLK1LRRK2PIK3CDPIK3C2GPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | Anhui Newstar Pharmaceutical Development Co., Ltd. (CN) | 2022-09-08 | — | — | US | disclosed |
| US-10975092-B2 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2021-04-13 | — | — | US | disclosed |
| EP-3738964-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | Dana Farber Cancer Institute, Inc. (US) | 2020-11-18 | — | — | EP | disclosed |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-09-29 | — | — | US | disclosed |
| US-20200115386-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | Anhui New Star Pharmaceutical Development Co., Ltd . (CN) | 2020-04-16 | — | — | US | disclosed |
| US-20200071340-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-03-05 | — | — | US | disclosed |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20190084998-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-03-21 | — | — | US | disclosed |
| US-10189861-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| EP-3424929-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | Anhui New Star Pharmaceutical Development Co., Ltd (CN) | 2019-01-09 | — | — | EP | disclosed |
| US-20170283422-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-10-05 | — | — | US | disclosed |
| US-9676792-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200071340-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885PIK3CD 412/4885 |
| US-20190084998-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885PIK3CD 412/4885 |
| US-10787461-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885PIK3CD 412/4885 |
| US-10189861-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885PIK3CD 412/4885 |
| US-20170283422-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885PIK3CD 412/4885 |
| US-10975092-B2 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | MST1, STK11, MSTN | DCLK1 796/4885LRRK2 143/4885PIK3CD 309/4885 |
| US-10457692-B2 | Pyrimido-diazepinone compounds and methods of treating disorders | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885PIK3CD 412/4885 |
| US-20160024115-A1 | PYRIMIDO-DIAZEPINONE COMPOUNDS AND METHODS OF TREATING DISORDERS | BRSK2, GRK3, BRSK1 | DCLK1 483/4885LRRK2 324/4885PIK3CD 412/4885 |
| US-20200115386-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | MST1, STK11, MSTN | DCLK1 796/4885LRRK2 143/4885PIK3CD 309/4885 |
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | MST1, MSTN, MST1R | DCLK1 1387/4885LRRK2 329/4885PIK3CD 2015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.